May 7, 2026 07:39AM
Apr 9, 2026 07:31AM
Apr 9, 2026 07:30AM
Feb 27, 2026 07:30AM
Feb 23, 2026 08:17AM
Feb 23, 2026 07:01AM
Feb 23, 2026 07:00AM ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
Jan 15, 2026 08:41AM
Jan 15, 2026 08:32AM
Jan 15, 2026 08:30AM
Nov 5, 2025 01:58AM
Nov 4, 2025 10:12PM
Aug 5, 2025 07:31AM
Aug 5, 2025 07:00AM ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
Jul 25, 2025 06:00AM
May 12, 2025 06:36AM
May 12, 2025 06:30AM
Apr 15, 2025 08:01AM
Apr 15, 2025 08:00AM
Mar 3, 2025 04:23PM
Mar 3, 2025 07:30AM ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
Nov 12, 2024 04:33PM
Nov 12, 2024 07:15AM
Mar 25, 2024 08:21AM
Jul 21, 2023 09:00PM
Jul 16, 2023 08:58PM
Nov 17, 2022 09:00AM
Nov 8, 2021 04:11PM Amyris, Inc. Reports Third Quarter 2021 Financial Results
Mar 15, 2021 09:09AM

1,199,633 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All